img

Global Peripheral Arterial Disease (PAD) Therapeutics Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Peripheral Arterial Disease (PAD) Therapeutics Market Research Report 2024

Peripheral artery disease (PAD) is a narrowing of the arteries other than those that supply the heart or the brain. When narrowing occurs in the heart, it is called coronary artery disease, while, in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication. Other symptoms including skin ulcers, bluish skin, cold skin, or poor nail and hair growth may occur in the affected leg. Complications may include an infection or tissue death which may require amputation; coronary artery disease, or stroke.[3] Up to 50% of cases of PAD are without symptoms.
According to MRAResearch’s new survey, global Peripheral Arterial Disease (PAD) Therapeutics market is projected to reach US$ 4249.9 million in 2033, increasing from US$ 2940 million in 2022, with the CAGR of 5.3% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Peripheral Arterial Disease (PAD) Therapeutics market research.
Key companies engaged in the Peripheral Arterial Disease (PAD) Therapeutics industry include AstraZeneca Plc. (UK), Bayer HealthCare Pharmaceuticals (Germany), Bristol-Myers Squibb Company (US), Merck & Co., Inc. (US), Proteon Therapeutics, Inc. (US), Sanofi S.A. (France), Symic Bio, Inc. (US), TheraVasc Inc. (US) and AnGes MG, Inc. (Japan), etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Peripheral Arterial Disease (PAD) Therapeutics were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Peripheral Arterial Disease (PAD) Therapeutics market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Peripheral Arterial Disease (PAD) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)
Segment by Type
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others

Segment by Application


Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Peripheral Arterial Disease (PAD) Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Anti-Platelet Drugs
1.2.3 Dual Antiplatelet Therapy Drugs
1.2.4 Others
1.3 Market by Application
1.3.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Perspective (2018-2033)
2.2 Peripheral Arterial Disease (PAD) Therapeutics Growth Trends by Region
2.2.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Region (2024-2033)
2.3 Peripheral Arterial Disease (PAD) Therapeutics Market Dynamics
2.3.1 Peripheral Arterial Disease (PAD) Therapeutics Industry Trends
2.3.2 Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
2.3.3 Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
2.3.4 Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue
3.1.1 Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peripheral Arterial Disease (PAD) Therapeutics Revenue
3.4 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio
3.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2022
3.5 Peripheral Arterial Disease (PAD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
3.7 Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Type
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2024-2033)
5 Peripheral Arterial Disease (PAD) Therapeutics Breakdown Data by Application
5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2033)
6.2 North America Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2023)
6.4 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2033)
7.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2023)
7.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2033)
8.2 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2033)
9.2 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size (2018-2033)
10.2 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca Plc. (UK)
11.1.1 AstraZeneca Plc. (UK) Company Detail
11.1.2 AstraZeneca Plc. (UK) Business Overview
11.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.1.4 AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.1.5 AstraZeneca Plc. (UK) Recent Development
11.2 Bayer HealthCare Pharmaceuticals (Germany)
11.2.1 Bayer HealthCare Pharmaceuticals (Germany) Company Detail
11.2.2 Bayer HealthCare Pharmaceuticals (Germany) Business Overview
11.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.2.4 Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Development
11.3 Bristol-Myers Squibb Company (US)
11.3.1 Bristol-Myers Squibb Company (US) Company Detail
11.3.2 Bristol-Myers Squibb Company (US) Business Overview
11.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.3.5 Bristol-Myers Squibb Company (US) Recent Development
11.4 Merck & Co., Inc. (US)
11.4.1 Merck & Co., Inc. (US) Company Detail
11.4.2 Merck & Co., Inc. (US) Business Overview
11.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.4.4 Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.4.5 Merck & Co., Inc. (US) Recent Development
11.5 Proteon Therapeutics, Inc. (US)
11.5.1 Proteon Therapeutics, Inc. (US) Company Detail
11.5.2 Proteon Therapeutics, Inc. (US) Business Overview
11.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.5.4 Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.5.5 Proteon Therapeutics, Inc. (US) Recent Development
11.6 Sanofi S.A. (France)
11.6.1 Sanofi S.A. (France) Company Detail
11.6.2 Sanofi S.A. (France) Business Overview
11.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.6.4 Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.6.5 Sanofi S.A. (France) Recent Development
11.7 Symic Bio, Inc. (US)
11.7.1 Symic Bio, Inc. (US) Company Detail
11.7.2 Symic Bio, Inc. (US) Business Overview
11.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.7.4 Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.7.5 Symic Bio, Inc. (US) Recent Development
11.8 TheraVasc Inc. (US)
11.8.1 TheraVasc Inc. (US) Company Detail
11.8.2 TheraVasc Inc. (US) Business Overview
11.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.8.4 TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.8.5 TheraVasc Inc. (US) Recent Development
11.9 AnGes MG, Inc. (Japan)
11.9.1 AnGes MG, Inc. (Japan) Company Detail
11.9.2 AnGes MG, Inc. (Japan) Business Overview
11.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.9.4 AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.9.5 AnGes MG, Inc. (Japan) Recent Development
11.10 Athersys, Inc. (US)
11.10.1 Athersys, Inc. (US) Company Detail
11.10.2 Athersys, Inc. (US) Business Overview
11.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.10.4 Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.10.5 Athersys, Inc. (US) Recent Development
11.11 Betagenon AB (Sweden)
11.11.1 Betagenon AB (Sweden) Company Detail
11.11.2 Betagenon AB (Sweden) Business Overview
11.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.11.4 Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.11.5 Betagenon AB (Sweden) Recent Development
11.12 miRagen Therapeutics, Inc. (US)
11.12.1 miRagen Therapeutics, Inc. (US) Company Detail
11.12.2 miRagen Therapeutics, Inc. (US) Business Overview
11.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.12.4 miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.12.5 miRagen Therapeutics, Inc. (US) Recent Development
11.13 Multi Gene Vascular Systems Ltd (Israel)
11.13.1 Multi Gene Vascular Systems Ltd (Israel) Company Detail
11.13.2 Multi Gene Vascular Systems Ltd (Israel) Business Overview
11.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.13.4 Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Development
11.14 ViroMed Co. Ltd. (Korea)
11.14.1 ViroMed Co. Ltd. (Korea) Company Detail
11.14.2 ViroMed Co. Ltd. (Korea) Business Overview
11.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Introduction
11.14.4 ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
11.14.5 ViroMed Co. Ltd. (Korea) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Anti-Platelet Drugs
Table 3. Key Players of Dual Antiplatelet Therapy Drugs
Table 4. Key Players of Others
Table 5. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2018-2023)
Table 9. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2024-2033)
Table 11. Peripheral Arterial Disease (PAD) Therapeutics Market Trends
Table 12. Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
Table 13. Peripheral Arterial Disease (PAD) Therapeutics Market Challenges
Table 14. Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
Table 15. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players (2018-2023)
Table 17. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2022)
Table 18. Ranking of Global Top Peripheral Arterial Disease (PAD) Therapeutics Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Peripheral Arterial Disease (PAD) Therapeutics Product Solution and Service
Table 22. Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2018-2023)
Table 26. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type (2024-2033)
Table 28. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2018-2023)
Table 30. Global Peripheral Arterial Disease (PAD) Therapeutics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2024-2033)
Table 32. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 33. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 35. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 38. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 39. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region (2024-2033) & (US$ Million)
Table 41. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 42. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 44. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 47. AstraZeneca Plc. (UK) Company Detail
Table 48. AstraZeneca Plc. (UK) Business Overview
Table 49. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 50. AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 51. AstraZeneca Plc. (UK) Recent Development
Table 52. Bayer HealthCare Pharmaceuticals (Germany) Company Detail
Table 53. Bayer HealthCare Pharmaceuticals (Germany) Business Overview
Table 54. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 55. Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 56. Bayer HealthCare Pharmaceuticals (Germany) Recent Development
Table 57. Bristol-Myers Squibb Company (US) Company Detail
Table 58. Bristol-Myers Squibb Company (US) Business Overview
Table 59. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 60. Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 61. Bristol-Myers Squibb Company (US) Recent Development
Table 62. Merck & Co., Inc. (US) Company Detail
Table 63. Merck & Co., Inc. (US) Business Overview
Table 64. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 65. Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 66. Merck & Co., Inc. (US) Recent Development
Table 67. Proteon Therapeutics, Inc. (US) Company Detail
Table 68. Proteon Therapeutics, Inc. (US) Business Overview
Table 69. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 70. Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 71. Proteon Therapeutics, Inc. (US) Recent Development
Table 72. Sanofi S.A. (France) Company Detail
Table 73. Sanofi S.A. (France) Business Overview
Table 74. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 75. Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 76. Sanofi S.A. (France) Recent Development
Table 77. Symic Bio, Inc. (US) Company Detail
Table 78. Symic Bio, Inc. (US) Business Overview
Table 79. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 80. Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 81. Symic Bio, Inc. (US) Recent Development
Table 82. TheraVasc Inc. (US) Company Detail
Table 83. TheraVasc Inc. (US) Business Overview
Table 84. TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 85. TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 86. TheraVasc Inc. (US) Recent Development
Table 87. AnGes MG, Inc. (Japan) Company Detail
Table 88. AnGes MG, Inc. (Japan) Business Overview
Table 89. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 90. AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 91. AnGes MG, Inc. (Japan) Recent Development
Table 92. Athersys, Inc. (US) Company Detail
Table 93. Athersys, Inc. (US) Business Overview
Table 94. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 95. Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 96. Athersys, Inc. (US) Recent Development
Table 97. Betagenon AB (Sweden) Company Detail
Table 98. Betagenon AB (Sweden) Business Overview
Table 99. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 100. Betagenon AB (Sweden) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 101. Betagenon AB (Sweden) Recent Development
Table 102. miRagen Therapeutics, Inc. (US) Company Detail
Table 103. miRagen Therapeutics, Inc. (US) Business Overview
Table 104. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 105. miRagen Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 106. miRagen Therapeutics, Inc. (US) Recent Development
Table 107. Multi Gene Vascular Systems Ltd (Israel) Company Detail
Table 108. Multi Gene Vascular Systems Ltd (Israel) Business Overview
Table 109. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 110. Multi Gene Vascular Systems Ltd (Israel) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 111. Multi Gene Vascular Systems Ltd (Israel) Recent Development
Table 112. ViroMed Co. Ltd. (Korea) Company Detail
Table 113. ViroMed Co. Ltd. (Korea) Business Overview
Table 114. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Product
Table 115. ViroMed Co. Ltd. (Korea) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023) & (US$ Million)
Table 116. ViroMed Co. Ltd. (Korea) Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Type: 2022 VS 2033
Figure 3. Anti-Platelet Drugs Features
Figure 4. Dual Antiplatelet Therapy Drugs Features
Figure 5. Others Features
Figure 6. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 7. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application: 2022 VS 2033
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Others Case Studies
Figure 11. Peripheral Arterial Disease (PAD) Therapeutics Report Years Considered
Figure 12. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region: 2022 VS 2033
Figure 15. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Players in 2022
Figure 16. Global Top Peripheral Arterial Disease (PAD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral Arterial Disease (PAD) Therapeutics as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Peripheral Arterial Disease (PAD) Therapeutics Revenue in 2022
Figure 18. North America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2018-2033)
Figure 20. United States Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Canada Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2018-2033)
Figure 24. Germany Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. France Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. U.K. Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Italy Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Russia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Nordic Countries Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Share by Region (2018-2033)
Figure 32. China Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. South Korea Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. India Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Australia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2018-2033)
Figure 40. Mexico Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Brazil Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Share by Country (2018-2033)
Figure 44. Turkey Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. AstraZeneca Plc. (UK) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 47. Bayer HealthCare Pharmaceuticals (Germany) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 48. Bristol-Myers Squibb Company (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 49. Merck & Co., Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 50. Proteon Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 51. Sanofi S.A. (France) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 52. Symic Bio, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 53. TheraVasc Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 54. AnGes MG, Inc. (Japan) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 55. Athersys, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 56. Betagenon AB (Sweden) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 57. miRagen Therapeutics, Inc. (US) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 58. Multi Gene Vascular Systems Ltd (Israel) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 59. ViroMed Co. Ltd. (Korea) Revenue Growth Rate in Peripheral Arterial Disease (PAD) Therapeutics Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries